Opendata, web and dolomites

PD UpReg SIGNED

Gene knock-up via 3’UTR targeting to treat Parkinson’s disease

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PD UpReg project word cloud

Explore the words cloud of the PD UpReg project. It provides you a very rough idea of what is the project "PD UpReg" about.

life    therapeutic    neuronal    gene    genes    unlike    experiments    editing    transgenics    elevation    physiologically    cells    ntfs    potent    strategy    degeneration    concurrently    deploy    shown    spatiotemporal    adult    protects    suggesting    utr    upregulate    ectopic    death    pattern    proof    mouse    pd    overexpressed    expression    therapy    restricted    attempts    safe    function    ectopically    protect    hypothesize    elderly    adulthood    causes    synuclein    dopaminergic    disease    least    neurotrophic    revolutionary    models    treating    experimentally    mice    upregulating    elevated    parkinson       defects    crispr    validation    progress    alpha    thereby    made    axons    toward    first    treat    endogenous    instead    incurable    gdnf    model    levels    restore    overexpressing    provides    mitochondrial    cas9    persons    limited    collectively    humans    mediated    appropriate    met    create    treatment    proteostasis    pathogenesis   

Project "PD UpReg" data sheet

The following table provides information about the project.

Coordinator
HELSINGIN YLIOPISTO 

Organization address
address: YLIOPISTONKATU 3
city: HELSINGIN YLIOPISTO
postcode: 14
website: www.helsinki.fi

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Finland [FI]
 Total cost 1˙999˙987 €
 EC max contribution 1˙999˙987 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2016-COG
 Funding Scheme ERC-COG
 Starting year 2017
 Duration (year-month-day) from 2017-09-01   to  2022-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    HELSINGIN YLIOPISTO FI (HELSINGIN YLIOPISTO) coordinator 1˙999˙987.00

Map

 Project objective

Parkinson’s disease (PD) affects 1% of elderly persons and is currently incurable. PD pathogenesis is driven, at least in part, by defects in proteostasis and mitochondrial function, leading to degeneration of dopaminergic axons and neuronal death. Neurotrophic factors (NTFs) such as GDNF can protect and restore dopaminergic axons. However, attempts to deploy NTFs ectopically in therapy models, or to increase proteostasis and mitochondrial function, have met with only limited success. I hypothesize that instead of ectopic application, over-expression of relevant pathways restricted to physiologically appropriate cells provides a potent therapeutic approach to treat PD. I have made significant progress toward this goal by targeting the 3’UTR in the mouse Gdnf gene, thereby increasing expression levels without affecting the gene’s spatiotemporal expression pattern. Using this approach I have shown that elevation of endogenous GDNF levels protects mice from experimentally induced PD. Unlike ectopic GDNF application, it causes no side effects. Importantly, I have established that GDNF levels can be elevated by 3’UTR targeting in adulthood, suggesting that this strategy could be applied in humans late in life. I will use 3’UTR targeting to study the therapeutic potential of overexpressing endogenous genes, using transgenics and CRISPR-Cas9‒mediated 3’UTR editing in adult mice. First, I will increase the expression of NTFs in adult mice with experimentally induced PD. Next, I will upregulate genes important in mitochondrial function and proteostasis and test whether concurrently upregulating endogenous NTFs is a viable approach for treating PD. Third, I will use 3’UTR targeting to create a mouse model of PD in which alpha-synuclein is overexpressed, for better validation of my therapeutic strategy. Collectively, these experiments should establish proof of concept for a revolutionary, safe and effective treatment for PD.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PD UPREG" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PD UPREG" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

evolSingleCellGRN (2019)

Constraint, Adaptation, and Heterogeneity: Genomic and single-cell approaches to understanding the evolution of developmental gene regulatory networks

Read More  

HEIST (2020)

High-temperature Electrochemical Impedance Spectroscopy Transmission electron microscopy on energy materials

Read More  

RODRESET (2019)

Development of novel optogenetic approaches for improving vision in macular degeneration

Read More